[5-FU concentration in blood and tissue of patients with primary lung cancer after oral administration of UFT].
Concentration of FT-207, 5-FU and Uracil in blood and normal lung tissue were estimated for lung cancer patients to whom UFT was orally administered. The histological types of these cases were as follows: 10 squamous cell carcinomas, 10 adenocarcinomas, 2 large cell carcinomas and 1 small cell carcinoma. Average concentration of 5-FU in these tumor tissues was 0.101 +/- 0.107 microgram/g. This was a significantly higher 5-FU concentration in comparison to those in serum and normal lung tissue. Comparison of 5-FU concentration between squamous cell carcinomas and adenocarcinomas showed no significant difference. Between metastasis-positive lymph nodes and metastasis-negative lymph nodes, there was also no significant difference in 5-FU concentration, but there was a significant difference in Uracil concentration. This result showed an effective transition of 5-FU from serum to tumor tissues with oral administration of UFT. It was therefore concluded that UFT would be expected to have an antitumor effect in primary lung cancer patients.
Oiwa
T
T
Saito
H
H
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008168:Lung / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism; D014498:Uracil / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism
D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil